Global

‡ In these countries please contact our distributor

Smith & Nephew and Osiris

New evidence at SAWC 2019

New evidence to be presented by Smith & Nephew at SAWC Spring and WHS in San Antonio, Texas with our recently acquired partner, Osiris Therapeutics, Inc.

Osiris Therapeutics, Inc. is focused on developing and marketing regenerative medicine products for wound care, orthopaedics, and sports medicine and the scientific content will complement that which will be presented by Smith & Nephew.

Clinical posters and symposiums will highlight new developments for Smith & Nephew in the negative pressure wound therapy arena and biofilm treatment. Additionally, the benefits of Osiris’ placenta-based products will be featured.

Poster presentations

Healthcare Resource Utilization of Stage 3 & Stage 4 Pressure Ulcer (PU) and Diabetic Foot Ulcer (DFU) Patients Treated Early with Clostridial Collagenase Ointment (CCO)
Ankur Patel, Health Economics Analyst, Smith & Nephew
How the use of Collagenase SANTYL Ointment leads to lower costs and less use of SANTYLin stage 3 and 4 pressure ulcers and diabetic foot ulcers when compared to utilizing SANTYL at a later start date.

Identification and Cost of Diagnostic Tests for Infection in Diabetic Foot Ulcers, Pressure Ulcers, and Venous Leg Ulcers
Ankur Patel, Health Economics Analyst, Smith & Nephew
Study results of 82,624 patients with 239,764 wounds  whose wounds had culture tests were consistently sicker than those patients whose wounds did not receive culture tests based on comorbidities.  27.3% of wounds had at least one culture test.

The Incremental Cost of Surgical Site Complications & Infections Across Multiple Surgical Indications
Ankur Patel, Health Economics Analyst, Smith & Nephew
Comparison of the cost and length of stay between patents with surgical site infections, as compared to those with non-surgical site infections.

Retrospective Analysis of Negative Pressure Usage in Hospitals
Ankur Patel, Health Economics Analyst, Smith & Nephew
An analysis of negative pressure usage in hospitals. 73.7% of patients were considered to have potential eligibility to switch to single use devices, with 55.1% of spend considered moveable to a lower cost alternative.

A Multicenter, Randomized, Single-Blind Trial Comparing the Efficacy of Viable Cryopreserved Placental Membrane to Human Fibroblast-Derived Dermal Substitute for the Treatment of Chronic Diabetic Foot Ulcers
Charles E. Ananian, DPM, Yadwinder S. Dhillon, MD, Carl C. Van Gils, DPM, D. Craig Lindsey, MD, Raymond J. Otto, MD, Cyaandi R. Dove, DPM, Jessica T. Pierce, MD, Molly C. Saunders
Results of a multicenter, prospective, randomized, single-blind trial comparing clinical outcomes and product cost between Grafix and Dermagraft in the treatment of chronic diabetic foot ulcers (DFUs).

Management of a Chronic Radiation Necrosis Wound with Lyopreserved Placental Membrane Containing Viable Cells
Matthew J. Regulski, DPM, Alla Danilkovitch, PhD, Molly C. Saunders
Management of a chronic radiation wound in a patient with multiple comorbidities using a lyopreserved placental membrane containing viable cells. Positive outcomes suggest that the lyopreserved placental membrane provides a good conservative management option for patients with compromised wound healing due to radiation and comorbidities.

A Prospective, Single-Center, Open-Label Case Series Evaluating the Clinical Outcomes of Lyopreserved Placental Membrane Containing Viable Cells for the Treatment of Chronic Wounds
Alexander M. Reyzelman, DPM; Mher Vartivarian, DPM; Alla Danilkovitch, PhD; Molly C. Saunders
A case series reporting the clinical outcomes of a lyopreserved placental membrane containing viable cells for the management of 11 chronic wounds. Results of this study demonstrate similar closure rates to those previously reported for cryopreserved placental membrane containing viable cells. These results suggest potential clinical equivalence between the 2 formulations, with the lyopreserved formulation providing the added convenience of long-term ambient storage.

Evaluation of a Commercial Lyopreserved Placental Membrane Containing Viable Cells in 10 Patients with a Range of Comorbidities and Wounds
Gary Gibbons, MD, FACS; Lisa Gould, MD, PhD, FACS; Cynthia Hernan, MSN, RN
A case series reporting the clinical outcomes of a lyopreserved placental membrane containing viable cells for the management of 11 wounds in 10 patients. Results demonstrate that lyopreserved placental membrane may be used as a good alternative in the management of acute and chronic wounds of various etiologies. Clinic office visit time was reduced as a result of the added convenience of room temperature storage.

Structure and Cell Viability of Lyophilized Amniotic Membrane are Equivalent to those of Cryopreserved Viable Amnion
Kathryn E. Davis, PhD, and Lawrence A. Lavery, DPM, MPH
Comparison of amnion lyophilized by the Prestige Lyotechnology (PL) method to cryopreserved amnion. Data show that the structure and cell viability of PL-lyophilized amnion are equivalent to those of cryopreserved viable amnion.

In Vitro Characterization of Human Lyopreserved Amniotic Membrane with Living Cells
Yong Mao, PhD, Tyler Hoffman, Amit Singal, Sandeep Dhall, PhD, Malathi Sathyamoorthy, PhD, Alla Danilkovitch, PhD, Joachim Kohn, PhD
A study investigating functionality of cells in amniotic tissue preserved using Prestige Lyopreservation. Results show that endogenous viable cells in lyopreserved amnion retain differentiation potential and anti-fibrotic activity in vitro post-lyophilization.

Injectable Cellular Placental Formulation prevents Bleomycin Induced Dermal Fibrosis in Aged Mice
Sandeep Dhall, PhD, Vimal Jacob, Reda Proctor, Brielle Johnson, Nicholas Johnson, Anne Lerch, Jin-Qiang Kuang, MD, Malathi Sathyamoorthy, PhD, Alla Danilkovitch, PhD
A poster highlighting anti-fibrotic effects of placental tissues in a model of bleomycin-induced dermal fibrosis in aged mice. Results of this study demonstrate that placental tissue might be a good option in the treatment of patients at higher risk for fibrosis due to aging, genetic predisposition, or exposure to radiation.


Smith & Nephew will be exhibiting at booth 516 and Osiris Therapeutics, Inc. at booth 525.

 

MSWE4-18205-0519

Conference and symposia schedule

Poster presentations

Clinical and scientific posters will be presented at the SAWC Spring and WHS Poster Gala and Award Ceremony from 7:15 pm to 8:45 pm on Thursday, May 9 in Hall 3.

Symposia schedule

Tuesday, May 7th 5:30pm – 7:00pm [Room 206]
Robert S. Kirsner, MD, PhD,  will present a lecture entitled “New Clinical Evidence that Changes the Game with NPWT” at a dinner symposium

Wednesday, May 8, noon – 1:30 pm [Room 210, onsite registration available]
Dan Davis, DPM, will present a lecture entitled “Grafix, GrafixPL & Stravix: Placental Tissues for Wound Care & Surgical Applications” at a lunch symposium

Wednesday, May 8, 12:30pm – 1:30pm [Room 207] 
Matthew Malone, FFPM, RCPS, will present a lecture entitled, “Prepare to Progress with IODOSORB: Myths and Reality of Biofilm, and the Legend of IODOSORB in Support of Chronic Wound Healing” at a lunch symposium

Thursday, May 9th 7:30am – 9:00am [Room 207]
Lee Ruotsi, MD, FACCWS, UHM, CWSP will deliver a breakfast symposium lecture entitled “Diabetic Neuropathic Ulcers Recognizing the Significant Burden and Reviewing a Treatment Option”

Register for SAWC and symposia >

Smith & Nephew and Osiris

Smith & Nephew expands in high growth regenerative medicine market through acquisition of Osiris Therapeutics, Inc.

Osiris is a fast growing company delivering regenerative medicine products including skin, bone graft and articular cartilage substitutes.

“With our combined portfolios, we will be presenting some truly exciting new evidence,” said Mike Zagger, SVP Advanced Wound Management at Smith & Nephew. “In addition to the new evidence from Osiris, we are focusing on new developments in negative pressure wound therapy and biofilm treatment. We look forward to fruitful conversations with attending clinicians about how we can help reduce the human and economic consequences of wounds.”

Read more >